Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings

AIDS

Volumn 18, Issue 6, 2004, Pages 939-943

  Stringer, Jeffrey S A ^a,b,c   Sinkala, Moses ^a,c,d   Goldenberg, Robert L ^a,c   Kumwenda, Rosemary ^e   Acosta, Edward P ^a   Aldrovandi, Grace M ^a   Stout, Julia P ^a,c   Vermund, Sten H ^a,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ZAMBIA   (Zambia)

^c CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^d MINISTRY OF HEALTH   (Zambia)

^e UNITED NATIONS DEVELOPMENT PROGRAMME   (United States)

Author keywords

Adherence; AIDS; Directly observed therapy; HIV; Mother to child; Nevirapine; Perinatal; Universal; Voluntary counseling and testing; Zambia

Indexed keywords

DNA; NEVIRAPINE;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SELF ADMINISTRATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABOR; MEASUREMENT; NEWBORN; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SERODIAGNOSIS; UMBILICAL CORD BLOOD; VERTICAL TRANSMISSION;

ADULT; ANTI-HIV AGENTS; DEVELOPING COUNTRIES; DIRECTLY OBSERVED THERAPY; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; NEVIRAPINE; PREGNANCY; PROSPECTIVE STUDIES; ZAMBIA;

EID: 2142810155     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200404090-00012     Document Type: Article

References (14)

1. United Nations General Assembly. Final declaration of commitment on HIV/AIDS (A/s-26/L.2). New York: United Nations; 2001.
2. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003, 362:859-868.
3. Buyse D, Nuwaha F, Karlin T, Wilfert. Prevention of mother to child HIV transmission: from research to action. XIV International AIDS Conference, Barcelona, July 2002 [abstract TuPeF5413].
4. Stringer EM, Sinkala M, Stringer JSA, Mzyece E, Makuka I, Goldenberg RL, et al. Prevention of mother-to-child transmission of HIV in Africa: Successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia. AIDS 2003, 17:1377-1382.
5. Stringer JSA, Sinkala M, Stout J, Goldenberg R, Acosta E, Chapman V, et al. Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings. J Acquir Immune Defic Syndr 2003, 32:506-513.
6. Stringer JSA, Rouse DJ, Vermund SH, Goldenberg RL, Sinkala M, Stinnett AA. Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa. J Acquir Immune Defic Syndr 2000, 24:369-377.
7. Stringer JSA, Stinnett AA, Rouse DJ, Srikala M, Goldenberg RL, Vermund SH. Cost-effectiveness of two novel strategies of perinatal nevirapine administration for women who deliver preterm or lack prenatal care. XIII International AIDS Conference, Durban, South Africa, 9-14 July 2000. Abstract C-620.
8. Marseille E, Kahn J, Mmiro F, Guay L, Musoke P, Fowler M, et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet 1999, 354:803-809.
9. Jayaraj A, Alexander J, Price C, Daly D, Pav J, Hattox S, et al. A rapid and sensitive HPLC-UV method for the quantitation of an anti-HIV agent, nevirapine, and its solid phase extractable metabolites in biological fluids. Pharm Res 1992, 9:s334.
10. Stringer JS, Sinkala M, Goldenberg RL, Stout JP, Kumwenda R, Mwinga KG, et al. A pilot study of nevirapine administered upon presentation in labor without HIV testing. Third Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants, Kampala, Uganda. September 2001 [abstract 300].
11. Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type-1. J Infect Dis 2003, 187:725-735.
12. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999, 354:795-802.
13. De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: Translating research into policy and practice. JAMA 2000, 283:1175-1182.
14. Stringer JSA, Sinkala M, Chapman V, Acosta E, Aldrovandi GM, Mudenda V, et al. Timing of the maternal drug dose and other risk factors for perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS 2003, 17:1659-65.